Do Not Stop Rosuvastatin – Continue the Statin and Investigate the eGFR Decline
The rosuvastatin should be continued, not stopped, as the eGFR decline from 65 to 51 mL/min/1.73 m² over 3 months is unlikely to be caused by the statin and requires investigation for other causes. This patient's renal function decline is too rapid and too severe to be attributed to rosuvastatin, which typically stabilizes or even improves eGFR in patients with CKD.
Why Rosuvastatin Is Not the Culprit
Evidence Supporting Continuation of Statins in CKD
Rosuvastatin typically improves or stabilizes eGFR, not worsens it. In controlled trials, rosuvastatin increased eGFR by +0.8 mL/min/1.73 m² compared to placebo, which showed a decline of -1.5 mL/min/1.73 m² 1.
High-intensity statins specifically improve eGFR in CKD patients. Meta-analysis demonstrates that high-intensity statins significantly increase eGFR with a mean difference of 3.35 mL/min/1.73 m² compared to control 2.
Long-term rosuvastatin treatment arrests progression of renal disease. In patients treated for ≥96 weeks, eGFR remained unchanged or increased rather than decreased, regardless of baseline renal function 3.
The magnitude of this patient's decline (14 mL/min/1.73 m² in 3 months) is inconsistent with statin effects. Studies show statins slow the rate of eGFR decline by approximately 0.5 mL/min/1.73 m² per year compared to placebo 4.
FDA Labeling Guidance on Rosuvastatin and Renal Function
Rosuvastatin is not contraindicated in moderate CKD (eGFR 30-60 mL/min/1.73 m²). The FDA label states that "mild to moderate renal impairment (CLcr ≥30 mL/min/1.73 m²) had no influence on plasma concentrations of rosuvastatin" 5.
Dose adjustment is only required for severe renal impairment (eGFR <30 mL/min/1.73 m²), where the starting dose should be 5 mg daily and not exceed 10 mg daily 5.
This patient's current eGFR of 51 mL/min/1.73 m² does not warrant dose reduction or discontinuation based on FDA guidance 5.
What You Should Do Instead
Immediate Actions Required
Confirm the eGFR decline with cystatin C-based measurement. KDIGO 2024 guidelines specifically recommend confirming any eGFR of 45-59 mL/min/1.73 m² using cystatin C and creatinine-based eGFR 6.
Assess for urine albumin-to-creatinine ratio (UACR) to determine if there is new or worsening proteinuria, which would suggest intrinsic kidney disease rather than statin effect 6.
Review for acute kidney injury causes:
- NSAIDs, ACE inhibitors/ARBs (check if recently started or dose increased)
- Dehydration or volume depletion
- Contrast exposure
- Other nephrotoxic medications
- Urinary obstruction
Check for pre-renal causes: The BUN/creatinine ratio of 12.5 is at the lower end of normal, making pre-renal azotemia less likely, but volume status should still be assessed clinically.
Long-Term Management Strategy
Continue rosuvastatin at current dose for cardiovascular protection, as the cholesterol improvement demonstrates efficacy and the patient needs ongoing ASCVD risk reduction 7.
If UACR ≥200 mg/g is present, strongly consider adding an SGLT2 inhibitor (if not already on one), as KDIGO 2024 recommends SGLT2i for adults with CKD and eGFR ≥20 mL/min/1.73 m² with albuminuria ≥200 mg/g 6.
Monitor eGFR more frequently (every 3 months) until the trajectory stabilizes, as this rapid decline warrants closer surveillance 6.
Optimize blood pressure control if hypertension is present, as uncontrolled hypertension is a common cause of accelerated eGFR decline in this age group.
Common Pitfalls to Avoid
Do not reflexively blame statins for eGFR decline. The evidence overwhelmingly shows statins are renoprotective, not nephrotoxic 2, 1, 3, 4.
Do not stop cardiovascular protective therapy without clear indication. This patient's improved cholesterol demonstrates the statin is working for its intended purpose 7.
Do not ignore the rapidity of decline. A 14 mL/min/1.73 m² drop in 3 months represents approximately 56 mL/min/1.73 m² per year if sustained—this is pathologic and requires investigation 6.
Do not forget to check for medication interactions. Review all medications for potential nephrotoxins or drug-drug interactions that could affect rosuvastatin levels 5.